Arcus Biosciences, Inc. Shareholders' Equity
Arcus Biosciences, Inc. (RCUS) had Shareholders' Equity of $464.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $464.00M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $524.00M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $631.00M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $436.00M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $464.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $524.00M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $631.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $436.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $549.00M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $531.00M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $485.00M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $565.00M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $635.00M 10-Q · filed 2025-10-28 | |
| 2024-03-31 | $707.00M 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $462.00M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $520.00M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $566.00M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $600.00M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $657.00M 10-K · filed 2026-02-25 | |
| 2022-09-30 | $699.00M 10-Q · filed 2023-11-07 | $698.70M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $747.00M 10-Q · filed 2023-11-07 | $747.39M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $797.00M 10-Q · filed 2023-11-07 | $796.58M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $842.00M 10-K · filed 2025-02-25 | $841.45M 10-K · filed 2022-02-23 |
| 2021-09-30 | $542.61M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $604.55M 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $664.79M 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $502.00M 10-K · filed 2024-02-21 | $502.30M 10-K · filed 2021-02-25 |
| 2020-09-30 | $544.42M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $428.71M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $140.64M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $164.00M 10-K · filed 2023-02-28 | $163.84M 10-K · filed 2020-03-05 |
| 2019-09-30 | $177.23M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $196.65M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $221.57M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $234.94M 10-K · filed 2022-02-23 | |
| 2018-09-30 | $245.12M 10-Q · filed 2019-11-05 | $245.12M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $254.57M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $266.59M 10-Q · filed 2019-11-05 | $266.59M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$72.33M 10-K · filed 2021-02-25 | |
| 2016-12-31 | -$19.99M 10-K · filed 2019-03-05 | |
| 2015-12-31 | -$2.17M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |